Fact CheckerSign in

NCT04716127Completed

A Proximity-incentive Strategy for Cervical Cancer Screening

Benefit From a Proximity-incentive Strategy Based on Vaginal Self-sampling for Women Who do Not Participate to Cervical Cancer Screening in Aude and Hérault [French Departments]: an Interventional Research to Reduce Social and Territorial Inequalities.

Source: ClinicalTrials.gov · Last updated 24 Apr 2026

Brief summary (registry, in English)

In France, cervical cancer screening is based on a cervical smear for women aged 25 to 30 years and on High Risk- HPV (HR-HPV) testing for women aged 30 to 65 years. One of the main concerns in France is poor attendance to this screening program, up to 40% of women, which led French Health Authorities to implement population-based organized cervical cancer screening (DO CCU), based on remind letters, starting in 2019. Our project is a complementary strategy to DO CCU based on direct proposal of a vaginal self-sample device for HR-HPV testing to non-attendee women while attending health care centers. Our hypothesis is that contacting under-screened women directly and proposing them a self-sample device to be used at home will increase their participation to cervical cancer screening. This project will be held in the Departments of Hérault and Aude, which are among those in the region of Occitanie (south of France) with the lowest participation to cervical cancer screening. Women aged 50 to 65 years with no cervical smear and/or gynecological examination for more than three years, will be recruited in two sites: in a mobile unit for breast cancer screening implemented in the whole Department of Hérault and in a Medical and Social Care located in a particularly deprived area of Aude (Limoux-Quillan). In each site, non attendee-women will be proposed by a trained mid-wife, a vaginal self-sample device to perform at home and send back by mail to the laboratory of the Hospital of Montpellier, which will perform HR-HPV testing. Women with positive HR-HPV DNA test will be asked to perfom a cervical smear and completion of follow-up will be monitored. The primary objective of this study will be to evaluate attendance of under-screened women to vaginal self-sampling for cervical cancer screening, i.e. the number of women who accepted a self-sample device among women to whom it has been proposed. A second objective will be to analyse psycho-social factors associated with cervical cancer screening in this population of non-attendee women, i.e. their socio-economic environment and the way women perceive and are implicated in cervical cancer screening. This secondary objective will be based on a specific questionnaire at recruitment and on semi-directive phone interviews in a sub-group of women. The efficacy of this screening strategy (number of women who performed vaginal self sample and sent it to the laboratory, and number of women who completed follow-up in case of a positive HR-HPV test) will also be monitored. The number of women to be recruited is 660. The total estimated duration of the project is 60 months, including 24 months for women's recruitment. Expected results from this project are: * An increase in participation to cervical cancer screening of non-attendee women aged 50 to 65 years in the Departments of Hérault and Aude. * Women's education about cervical cancer screening through discussion with the midwife during recruitment and information tools developed for the project * Information of local health staff and community-based associations about cervical cancer screening and the place of HR-HPV testing. * Identification of psycho-social factors and potential barriers to compliance to cervical cancer screening. * Identification of organizational and practical difficulties that must be overcome to improve preventive actions towards deprived populations.

Status (registry)
Completed
Study type
Interventional
Enrollment
656 (actual)
First submitted
15 Jan 2021
Start date
16 Sept 2021
Primary completion date
25 Jul 2023
Lead sponsor
University Hospital, Montpellier
NCT number
NCT04716127

What you commit to

  • Study type: Interventional
  • Participants enrolled: 656
  • From 16 Sept 2021 to the primary completion date, 25 Jul 2023
  • 2 sites in 1 country
  • Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

  • History of hysterectomy
  • History of cervix pathology (conization, laser treatment of the cervix)
  • History of cervical cancer

Other

  • Women deprived of their liberty, protected adults or vulnerable persons
  • Known cervical lesion or known HPV status
  • Known immune-depression

Who the study is looking for

  • Asymptomatic women 50 to 65 years old (50 and 65 years included)
  • With no cervical smear (or gynecologic examination) or HPV test for at least 3 years (≥ 3 years)
  • Able to understand the study and provide voluntarily a written consent to participate
  • Able to understand and answer the questions of the study questionnaire by themselves or with the help of a self-chosen third party
  • Beneficiary of social security insurance

Age in the registry: 50 years to 65 years · Sex: Female · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (2)

Sites in registry order. Pick your city on the disease page to sort them by distance.

SiteCityCountrySite status
Arnaud de Villeneuve Hospital, clinical trials Department
Coordinator of this site? Confirm its status
MontpellierFranceUnknown status
Mammobile Hérault
Coordinator of this site? Confirm its status
MontpellierFranceUnknown status

This page is information, not medical advice. Discuss any trial with your doctor.